MA34369B1 - Agents anti-inflammatoires - Google Patents

Agents anti-inflammatoires

Info

Publication number
MA34369B1
MA34369B1 MA35547A MA35547A MA34369B1 MA 34369 B1 MA34369 B1 MA 34369B1 MA 35547 A MA35547 A MA 35547A MA 35547 A MA35547 A MA 35547A MA 34369 B1 MA34369 B1 MA 34369B1
Authority
MA
Morocco
Prior art keywords
compounds
inflammatory agents
relates
formulas
aromatic
Prior art date
Application number
MA35547A
Other languages
English (en)
Inventor
David John Grainger
David John Fox
Original Assignee
Cambridge Entpr Ltd
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42471347&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA34369(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cambridge Entpr Ltd, Boehringer Ingelheim Int filed Critical Cambridge Entpr Ltd
Publication of MA34369B1 publication Critical patent/MA34369B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/12—Nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/45—Non condensed piperidines, e.g. piperocaine having oxo groups directly attached to the heterocyclic ring, e.g. cycloheximide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/56—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Thiazole And Isothizaole Compounds (AREA)

Abstract

La présente invention concerne des méthodes de prévention ou de traitement de maladies inflammatoires, qui utilisent des analogues sulfonamides de composés 3-aminolactame, chacun avec des "groupes de queue" aromatiques. Les composés sont définis par les formules (I) et (''), et l'invention concerne également les usages médicaux des composés.
MA35547A 2010-06-08 2011-06-08 Agents anti-inflammatoires MA34369B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1009603.0A GB201009603D0 (en) 2010-06-08 2010-06-08 Anti-inflammatory agent
PCT/GB2011/000862 WO2011154695A1 (fr) 2010-06-08 2011-06-08 Agents anti-inflammatoires

Publications (1)

Publication Number Publication Date
MA34369B1 true MA34369B1 (fr) 2013-07-03

Family

ID=42471347

Family Applications (2)

Application Number Title Priority Date Filing Date
MA35548A MA34370B1 (fr) 2010-06-08 2011-06-08 Agents anti-inflammatoires
MA35547A MA34369B1 (fr) 2010-06-08 2011-06-08 Agents anti-inflammatoires

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA35548A MA34370B1 (fr) 2010-06-08 2011-06-08 Agents anti-inflammatoires

Country Status (21)

Country Link
US (2) US20130172318A1 (fr)
EP (2) EP2580196A1 (fr)
JP (2) JP2013531647A (fr)
KR (2) KR20130086952A (fr)
CN (2) CN103119021A (fr)
AP (2) AP2012006559A0 (fr)
AU (1) AU2011263531A1 (fr)
BR (2) BR112012030816A2 (fr)
CA (2) CA2798213A1 (fr)
CL (1) CL2012003460A1 (fr)
CO (2) CO6670553A2 (fr)
GB (1) GB201009603D0 (fr)
IL (2) IL222798A0 (fr)
MA (2) MA34370B1 (fr)
MX (2) MX2012014290A (fr)
PE (2) PE20130772A1 (fr)
PH (2) PH12012502167A1 (fr)
SG (2) SG185129A1 (fr)
TN (2) TN2012000521A1 (fr)
WO (2) WO2011154695A1 (fr)
ZA (2) ZA201208367B (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GEP20227402B (en) * 2017-09-07 2022-08-10 Valenta Intellekt Ltd Use of glutarimide derivative to treat diseases related to aberrant activity of cytokines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3054738B2 (ja) * 1988-07-22 2000-06-19 武田薬品工業株式会社 チアゾロ［５，４―ｂ］アゼピン誘導体
JPH03206042A (ja) 1990-01-06 1991-09-09 Takeda Chem Ind Ltd 降圧剤
IT1247698B (it) 1990-06-21 1994-12-30 Sigma Tau Ind Farmaceuti 1-alchil-3-(acilammino)-e-caprolattami quali attivatori dei processi di apprendimento e della memoria e composizioni farmaceutiche comprendenti tali composti
DE4117507A1 (de) * 1991-05-24 1992-11-26 Schering Ag Verfahren zur herstellung von n(pfeil hoch)6(pfeil hoch)-substituierten lysin-derivaten
JP3206042B2 (ja) 1991-10-31 2001-09-04 ミノルタ株式会社 新規トリアミノ化合物を用いた電荷輸送材料、このトリアミノ化合物を含有する感光体およびエレクトロルミネセンス素子
US6989435B2 (en) 1997-09-11 2006-01-24 Cambridge University Technical Services Ltd. Compounds and methods to inhibit or augment an inflammatory response
CA2363067C (fr) 1999-01-12 2012-03-20 David J. Grainger Composes et procedes destines a inhiber ou renforcer une reaction inflammatoire
AU2003269850A1 (en) 2002-10-08 2004-05-04 Novo Nordisk A/S Hemisuccinate salts of heterocyclic dpp-iv inhibitors
WO2004084898A1 (fr) * 2003-03-24 2004-10-07 Actimis Pharmaceuticals, Inc. Derives de 2-phenoxy- et 2-phenylsulfonamide a activite antagoniste de ccr3 pour le traitement de l'asthme et d'autres troubles inflammatoires ou immunologiques
CA2544350A1 (fr) 2003-10-29 2005-05-12 Elan Pharmaceuticals, Inc. Benzenesulfonamides n-substitues
CA2547651C (fr) 2003-12-01 2015-06-23 Cambridge University Technical Services Limited Agents anti-inflammatoires
AU2005261932B2 (en) * 2004-07-13 2011-10-13 F. Hoffmann-La Roche Ag Sulfonamide derivatives
GB2418425B (en) * 2004-08-11 2008-09-03 Univ Cambridge Tech Anti-inflammatory agents
GB2418426A (en) 2004-08-18 2006-03-29 Univ Cambridge Tech Alpha-(acylamino)-bicyclolactam derivatives for treatment of inflammatory disorders
GB2423085C (en) 2005-02-11 2011-11-09 Cambridge Entpr Ltd Ligands for G-protein coupled receptors
EP1896036B1 (fr) * 2005-06-15 2013-01-23 Cambridge Enterprise Limited Agents anti-inflammatoires
GB0512238D0 (en) 2005-06-15 2005-07-27 Univ Cambridge Tech Anti-inflammatory agents
EP1915345B1 (fr) 2005-08-12 2010-12-22 F. Hoffmann-La Roche AG Dérivés de 2-oxo-azépane substitués par du fluor
JP5335426B2 (ja) 2005-09-27 2013-11-06 アイアールエム・リミテッド・ライアビリティ・カンパニー ジアリールアミン含有化合物および組成物、ならびにｃ−ｋｉｔ受容体のモジュレーターとしてのそれらの使用
CA2694454A1 (fr) 2007-07-26 2009-02-05 Ipsen Pharma S.A.S. Analogues de la chimiokine
GB2452696B (en) 2007-08-02 2009-09-23 Cambridge Entpr Ltd 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions

Also Published As

Publication number Publication date
KR20130115082A (ko) 2013-10-21
PH12012502169A1 (en) 2013-01-07
GB201009603D0 (en) 2010-07-21
EP2580196A1 (fr) 2013-04-17
TN2012000521A1 (en) 2014-04-01
CL2012003460A1 (es) 2013-08-16
US20130172318A1 (en) 2013-07-04
JP2013531647A (ja) 2013-08-08
KR20130086952A (ko) 2013-08-05
MX2012014290A (es) 2013-05-01
AU2011263531A1 (en) 2012-11-22
IL222866A0 (en) 2012-12-31
BR112012030816A2 (pt) 2016-11-01
PE20131046A1 (es) 2013-09-23
WO2011154696A1 (fr) 2011-12-15
SG185129A1 (en) 2012-12-28
EP2580197A1 (fr) 2013-04-17
AP2012006559A0 (en) 2012-12-31
CN103119021A (zh) 2013-05-22
PE20130772A1 (es) 2013-07-03
MX2012014291A (es) 2013-05-01
CA2798129A1 (fr) 2011-12-15
CN103080090A (zh) 2013-05-01
CO6670569A2 (es) 2013-05-15
JP2013528201A (ja) 2013-07-08
ZA201208367B (en) 2013-10-30
BR112012031136A2 (pt) 2017-08-08
SG185130A1 (en) 2012-12-28
AP2012006560A0 (en) 2012-12-31
IL222798A0 (en) 2012-12-31
US20130203734A1 (en) 2013-08-08
PH12012502167A1 (en) 2013-01-07
MA34370B1 (fr) 2013-07-03
CO6670553A2 (es) 2013-05-15
CA2798213A1 (fr) 2011-12-15
ZA201208406B (en) 2013-07-31
WO2011154695A1 (fr) 2011-12-15
TN2012000525A1 (en) 2014-04-01

Similar Documents

Publication Publication Date Title
MX2023001538A (es) Composiciones y metodos para inhibir la expresion de lpa.
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
ECSP088852A (es) Azolopirimidinas como inhibidores de la actividad canabinoidea 1
ECSP067021A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
CR20110351A (es) Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cáncer y enfermedades inmunes
NI200900093A (es) Compuestos que modulan la actividad de c-fms y/o c-kit y uso de los mismos.
EA200971141A1 (ru) Соединения, активирующие теломеразу, и способы их применения
EA200900828A1 (ru) Соединения и композиции в качестве ингибиторов активности каннабиноидного рецептора 1
BRPI0517015A (pt) compostos e composições como inibidores de atividade de receptor 1 de canabinóide
BRPI0610108B8 (pt) compostos promotores de apoptose e composição que compreende os ditos compostos
UA95103C2 (ru) Замещенные арилсульфонамиды в качестве противовирусных средств
NO20070081L (no) Sulfamat og sulfamidderivater for behandling av epilepsi og relaterte sykdommer
DOP2013000130A (es) Compuestos de pirimidinona para uso en el tratamiento de las enfermedades o condiciones mediada por lp - pla2
PA8586001A1 (es) Derivados de indol útiles para el tratamiento de enfermedades
EA200602242A1 (ru) 3-аминоциклопентанкарбоксамиды в качестве модуляторов хемокиновых рецепторов
CO6321241A2 (es) Derivados de 1,3,4- tiadiazol espiro condensados para la inhibicion de la actividad de quinesina (ksp)
NI200700075A (es) Acidos 4-((fenoxialquil)tio)-fenoxiaceticos y analogos
JOP20230250A1 (ar) تركيبات وطرق لتثبيط إنزيم كيتوهيكسوكيناز (khk)
CO6630193A2 (es) Inhibidores de la actividad de la proteína tirosina quinasa seleccionada
ECSP067019A (es) Compuestos y composiciones como moduladores del receptor activado por proliferador de peroxisoma (ppar)
ECSP045277A (es) Composición oftálmica que comprende ascomicina
NO20074780L (no) Heterocyklylamidsubstituerte imidazoler
CL2010001566A1 (es) Compuesto derivado de piperidinilo, modulador de la actividad de los receptores de la quimiocina; composicion farmaceutica que los comprende; y su uso en el tratamiento de enfermedades inflamatorias, alergicas, autoinmune.
SV2011003839A (es) Agentes antifungicos
MX2012003693A (es) Composiciones de olopatadine y usos de las mismas.